Abcam Enters Cell Editing Market Through Acquisition of EdiGene’s Knock-out Cell Lines and Lysates Portfolio
Time:19-08-12 11:17
Form: Null
Views:527
From :https://www.abcam.com/index.html?pageconfig=resource&rid=17026
Largest off-the-shelf diploid KO library, over 2,800 cell lines
Cambridge, UK and Beijing, CN: 16 July, 2019 – Abcam plc, a global innovator in life science reagents and tools, is today pleased to announce the acquisition of the entire live cell line and lysates portfolio of EdiGene Inc, a leading company focused on developing genome editing technologies into novel therapeutics for a broad range of diseases and into creative solutions to advance drug discovery.
